tiprankstipranks
Advertisement
Advertisement

NMRA Stock Latest News

Neumora Shareholders Approve Directors, Auditor and Executive Pay
Company AnnouncementsNeumora Shareholders Approve Directors, Auditor and Executive Pay
6d ago
8K
NMRA
Analyst Reiterates Buy on Neumora, Maintaining $18 Price Target Ahead of Key KOASTAL-2/3 Depression Readouts
PremiumRatings
Analyst Reiterates Buy on Neumora, Maintaining $18 Price Target Ahead of Key KOASTAL-2/3 Depression Readouts
8d ago
NMRA
Neumora’s NMRA-323511 Alzheimer’s Agitation Study Reaches Completion, Setting Up the Next Investor Catalyst
PremiumCompany Announcements
Neumora’s NMRA-323511 Alzheimer’s Agitation Study Reaches Completion, Setting Up the Next Investor Catalyst
13d ago
NMRA
Neumora Therapeutics Securities Lawsuit Enters New Procedural Phase as Plaintiffs Prepare New Complaint
PremiumClass Action
Neumora Therapeutics Securities Lawsuit Enters New Procedural Phase as Plaintiffs Prepare New Complaint
17d ago
NMRA
Ami Fadia Reiterates Buy on Neumora, Sees Compelling Risk-Reward Ahead of Phase 3 Readouts with Unchanged $8 Price Target
PremiumRatings
Ami Fadia Reiterates Buy on Neumora, Sees Compelling Risk-Reward Ahead of Phase 3 Readouts with Unchanged $8 Price Target
21d ago
NMRA
Analyst Initiates Buy on Neumora, Citing Compelling Risk/Reward Ahead of Key Navacaprant Readouts and Broader Pipeline Upside
PremiumRatingsAnalyst Initiates Buy on Neumora, Citing Compelling Risk/Reward Ahead of Key Navacaprant Readouts and Broader Pipeline Upside
28d ago
NMRA
Neumora Therapeutics reports Q1 EPS (30c), consensus (31c)
Premium
The Fly
Neumora Therapeutics reports Q1 EPS (30c), consensus (31c)
28d ago
NMRA
Neumora: Deep Pipeline and Near‑Term Clinical Catalysts Support Attractive Risk‑Reward and Buy Rating
Premium
Ratings
Neumora: Deep Pipeline and Near‑Term Clinical Catalysts Support Attractive Risk‑Reward and Buy Rating
2M ago
NMRA
Neumora Therapeutics management to meet with Piper Sandler
PremiumThe Fly
Neumora Therapeutics management to meet with Piper Sandler
2M ago
NMRA
Neumora Therapeutics Maps High-Stakes Catalyst Road Ahead
PremiumCompany Announcements
Neumora Therapeutics Maps High-Stakes Catalyst Road Ahead
2M ago
NMRA
Neumora Therapeutics Warns Nasdaq Delisting Risk Could Hit Liquidity, Share Price, and Capital Access
PremiumCompany Announcements
Neumora Therapeutics Warns Nasdaq Delisting Risk Could Hit Liquidity, Share Price, and Capital Access
2M ago
NMRA
Midday Fly By: Sysco buying Restaurant Depot, Uber to acquire Blacklane
PremiumThe Fly
Midday Fly By: Sysco buying Restaurant Depot, Uber to acquire Blacklane
2M ago
IQ
SR
Options Volatility and Implied Earnings Moves Today, March 30, 2026
PremiumMarket NewsOptions Volatility and Implied Earnings Moves Today, March 30, 2026
2M ago
CBAT
DFDV
Neumora Therapeutics reports Q4 EPS (35c), consensus (33c)
Premium
The Fly
Neumora Therapeutics reports Q4 EPS (35c), consensus (33c)
2M ago
NMRA
NMRA Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
NMRA Earnings this Week: How Will it Perform?
3M ago
NMRA
Neumora Therapeutics management to meet virtually with Needham
PremiumThe Fly
Neumora Therapeutics management to meet virtually with Needham
3M ago
NMRA
Neumora upgraded to Outperform from Market Perform at William Blair
PremiumThe Fly
Neumora upgraded to Outperform from Market Perform at William Blair
4M ago
NMRA
Differentiated NMRA-511 Efficacy and Safety in Alzheimer’s Agitation Support Buy Rating on Neumora
PremiumRatings
Differentiated NMRA-511 Efficacy and Safety in Alzheimer’s Agitation Support Buy Rating on Neumora
4M ago
NMRA
Strengthening NMRA-511 Clinical Profile and Upside Potential Underpin Buy Rating and $18 Target
PremiumRatings
Strengthening NMRA-511 Clinical Profile and Upside Potential Underpin Buy Rating and $18 Target
4M ago
NMRA
Neumora outlines 2026 neuroscience pipeline and obesity plans
PremiumCompany AnnouncementsNeumora outlines 2026 neuroscience pipeline and obesity plans
5M ago
8K
NMRA
Diversified CNS Pipeline and NLRP3 Opportunity Drive Upside in Neumora: Justifying an Outperform/Buy Rating
Premium
Ratings
Diversified CNS Pipeline and NLRP3 Opportunity Drive Upside in Neumora: Justifying an Outperform/Buy Rating
5M ago
NMRA
Neumora Therapeutics initiated with an Outperform at Leerink
Premium
The Fly
Neumora Therapeutics initiated with an Outperform at Leerink
5M ago
NMRA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >